Histology of Luminal Breast Cancer

被引:20
|
作者
Erber, Ramona [1 ]
Hartmann, Arndt [1 ]
机构
[1] Friedrich Alexander Univ Erlangen Nurnberg FAU, Comprehens Canc Ctr Erlangen EMN, Univ Hosp Erlangen, Inst Pathol, Erlangen, Germany
关键词
Luminal A; Luminal B; Breast cancer; Estrogen receptor; Histological subtypes; INVASIVE CRIBRIFORM CARCINOMA; LOBULAR CARCINOMA; MICROPAPILLARY CARCINOMA; SEBACEOUS CARCINOMA; DUCTAL CARCINOMA; IN-SITU; CLINICOPATHOLOGICAL FEATURES; TUBULOLOBULAR CARCINOMA; MUCINOUS CARCINOMA; APOCRINE CARCINOMA;
D O I
10.1159/000509025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background:Invasive breast cancer (IBC) can be categorized into prognostic and predictive molecular subtypes (including luminal breast cancer) using gene expression profiling. Luminal IBC comprises a variety of histological subtypes with varying clinical and pathological features.Summary:IBC of no special subtype is the most common histological subtype in general and likewise within luminal IBC. Classical invasive lobular breast cancer, typically clustering into luminal subgroup, is characterized by discohesive growth and loss of E-cadherin expression. Infrequent, morphologically distinct luminal IBC subtypes are tubular, invasive cribriform, mucinous, and invasive micropapillary carcinomas. Breast carcinoma with apocrine differentiation, with characteristic expression of androgen receptor (AR), often clusters into the luminal AR category. Rarely, neuroendocrine neoplasms of the breast can be seen. IBC of the male breast usually matches with the luminal subtype.Key Messages:Independently from histological subtypes, invasive breast cancer (IBC) can be divided into molecular subtypes based on mRNA gene expression levels. Using this molecular subtyping, risk scores based on gene expression profiling (established for hormone receptor-positive, HER2-negative IBC), grading, and Ki-67 index, prognosis of patients with luminal breast cancer and response to chemotherapy can be predicted. In routine diagnostics, the expression of estrogen receptor (ER) and progesterone receptor (PR), HER2 status, and the proliferation rate (Ki-67) are used to determine a surrogate (molecular-like) subtype. Within luminal(-like) IBC, no special subtype and invasive lobular breast carcinoma are the most common histological subtypes. Other rare histological subtypes (e.g., tubular carcinoma) should be recognized due to their distinct clinical and pathological features.
引用
收藏
页码:327 / 336
页数:10
相关论文
共 50 条
  • [41] SYNCHRONOUS BREAST-CANCER WITH DIFFERENT HISTOLOGY
    HUSSAIN, ST
    ALLUM, WH
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1993, 86 (09) : 550 - 550
  • [42] Therapeutic strategies to induce ERα in luminal breast cancer to enhance tamoxifen efficacy
    Esakov, Emily L.
    Hale, James
    Richards, Elliott G.
    Torre-Healy, Luke
    Gullapalli, Keerthi
    Trivedi, Div
    Chumakova, Anastasia
    Wessely, Oliver
    Jensen, Jan
    Lathia, Justin
    Reizes, Ofer
    ENDOCRINE-RELATED CANCER, 2019, 26 (08) : 689 - 698
  • [43] Association of Proteasomal Activity with Metastasis in Luminal Breast Cancer
    Shashova, E. E.
    Fesik, E. A.
    Doroshenko, A. V.
    PHYSICS OF CANCER: INTERDISCIPLINARY PROBLEMS AND CLINICAL APPLICATIONS (PC IPCA), 2017, 1882
  • [44] Combined endocrine and targeted therapy in luminal breast cancer
    Goldner, Marcelle
    Pandolfi, Natasha
    Maciel, Debora
    Lima, Julianne
    Sanches, Solange
    Ponde, Noam
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (11) : 1237 - 1251
  • [45] Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype
    G Kristiansen
    M Rose
    C Geisler
    F R Fritzsche
    J Gerhardt
    C Lüke
    A-M Ladhoff
    R Knüchel
    M Dietel
    H Moch
    Z Varga
    J-P Theurillat
    T A Gorr
    E Dahl
    British Journal of Cancer, 2010, 102 : 1736 - 1745
  • [46] Luminal (Her2 negative) prognostic index and survival of breast cancer patients
    Chen, Xuesong
    Cong, Yingying
    Pan, Lihua
    Jiang, Ying
    Meng, Qingwei
    Sun, Lichun
    Pang, Hui
    Zhao, Yanbin
    Dong, Xiaoqun
    Cai, Li
    CANCER EPIDEMIOLOGY, 2014, 38 (03) : 286 - 290
  • [47] SIRT7 Is a Prognostic Biomarker Associated With Immune Infiltration in Luminal Breast Cancer
    Huo, Qin
    Li, Zhenwei
    Cheng, Lixin
    Yang, Fan
    Xie, Ni
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [48] Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer
    Xiao, Yuanting
    Zhang, Sheng
    Hou, Guofang
    Zhang, Xiaobei
    Hao, Xiaomeng
    Zhang, Jin
    TUMOR BIOLOGY, 2014, 35 (03) : 2035 - 2045
  • [49] SYCP2 expression is a novel prognostic biomarker in luminal A/B breast cancer
    Wu, Chihua
    Tuo, Youlin
    FUTURE ONCOLOGY, 2019, 15 (08) : 817 - 826
  • [50] Prognostic significance of malignant pleural effusions in patients with advanced luminal B breast cancer
    Han, You-ming
    Yan-Dong, Hai-long
    Wang, Hai-long
    Li, Xiang-Min
    Zhang, Xiao-
    Wei, Xin-Yu
    Qian, Feng-Wen
    Li, Zhi-Gang
    BMC WOMENS HEALTH, 2024, 24 (01)